Bolton, Monica Jane, Chapman, Bryan Paul, Van Marwijk, Harm · BMJ case reports · 2020 · DOI
This study describes three people with ME/CFS who tried taking low-dose naltrexone (LDN), a medication sometimes used off-label for immune-related conditions. The patients experienced different results—some reported major improvements in their quality of life, while others noticed only modest reductions in specific symptoms like pain or fatigue. The doses used were quite small (4-12 mg), and the authors suggest that larger clinical trials might be worth doing to properly test whether LDN could help ME/CFS patients.
ME/CFS currently has no FDA-approved or widely accepted pharmacological treatments, making exploration of any potentially beneficial option clinically important. This case series bridges the gap between internet-reported anecdotal success with LDN and rigorous clinical evidence, providing preliminary justification for funding controlled trials. Understanding which ME/CFS patients might respond to repurposed medications like naltrexone could offer hope to severely disabled patients seeking symptom management strategies.
This study cannot establish efficacy, causation, or safe dosing—it is three anecdotal reports without a control group, blinding, or objective outcome measures. The observed improvements may reflect placebo effect, natural variation in ME/CFS symptoms, concurrent lifestyle changes, or regression to the mean rather than naltrexone's pharmacological action. Extrapolating from three positive/partial responses to a general ME/CFS population would be premature without randomized controlled trial evidence.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.